具体而言,排除了已知携带EGFR,KRAS,BRAF或ERBB2突变或ALK或ROS1重排的患者。 其中,MET外显子14跳跃是最常见的突变,发生在10名患者(19%)中。腺癌和鳞状组织学均可见MET外显子14跳跃。一名患者共存PI3KCA E545K和CTNNB1突变。 RET和NRG1的重排也是该队列患者的常见事件。值得一提的是,两名被认为ALK阴性的患者PC...
EGFRi/METi 队列中的另一名患者发生CTNNB1 p.S45P突变。在最后一次随访时,即开始接受奥希替尼联合特泊替尼治疗后14.0个月,该患者仍然活着且无进展。 一名患者出现可检测到的PIK3CA p.E542A突变,并且在使用奥希替尼加特泊替尼不到1个月后出现病情进展。 在EGFRi/METi队列中未观察到MET、ERBB2(HER2)、KRAS和...
EGFRi/METi 队列中的另一名患者发生CTNNB1 p.S45P突变。在最后一次随访时,即开始接受奥希替尼联合特泊替尼治疗后14.0个月,该患者仍然活着且无进展。 一名患者出现可检测到的PIK3CA p.E542A突变,并且在使用奥希替尼加特泊替尼不到1个月后出现病情进展。 在EGFRi/METi队列中未观察到MET、ERBB2(HER2)、KRAS和...
The resultant mouse tumors showed similar transcriptomes to human HCC samples with concomitant CTNNB1 mutations and MET overexpression. These data argue that while dominantly activating mutants of β-catenin are oncogenic, inhibiting the oncogenic signaling pathway generates a prooncogenic microenvironment, ...
ERBB2突变的患者中NKX2-1扩增(19.4%),ERBB2扩增(14.4%)和RB1突变(8.9%)比较常见,而TP53 (51.7%), CDKN2A(27.2%), CDKN2B (17.2%), PIK3CA (5%) and CTNNB1(4.4%) 和MDM2 扩增 (7.2%)在ERBB2突变的患者中的占比与总体的非小细胞肺癌中的占比类似。
BRAFexons 11, 15,CTNNB1exon 3,DDR2exons 4–19,EGFRexons 18–21,ERBB2exons 19, 20,FGFR2exons 8–10, 12, 17, 20,FGFR3exons 7, 10, 15,KEAP1exons 2–6,KRAS2–4,MAP2K1exon 2,METexons 14, 16–19,NFE2L2exon 2,NRASexons 2–4;PIK3CAexons 9, 20,PTENexons 1–8,TP53exons 5–...
3. To genetically characterize the primary CRC using next generation sequencing (NGS) on a panel comprising 180 amplicons of 30 genes (including KRAS, BRAF, NRAS, APC, PIK3CA, TP53, CTNNB1 and EGFR) and determine their association with treatment response. 4. To study the treatment tolerability...
Both activating and inactivating mutations in ctnnb1, encoding -catenin, have been implicated in liver tumorigenesis in humans and mice, although the underlying mechanisms are not fully understood. Herein we show that deletion of endogen...
CTNNB1 mutation analysis was also carried out on all samples. We also investigated beta-catenin pathway activation in two liver cancer cell lines, HuH-6 and HuH-7. Aberrant beta-catenin expression was seen in the cytoplasm and/or nucleus of 87% of tumour samples. Our results also revealed ...
The gene expression of mouse tumors in hMet-mutant 尾-catenin showed high correlation, with subsets of human HCC displaying concomitant hMet activation signature and CTNNB1 mutations.We have identified cooperation of hMet and 尾-catenin activation in a subset of HCC patients and modeled this ...